Wills Eye deploys image management system

Article

Wills Eye Institute, Philadelphia, has chosen Topcon Medical Systems' new software (EyeRoute, Topcon) with the goal of improving workflow and ensuring seamless interconnectivity of its devices so that diagnostic information is made available virtually at any time from any location.

Key Points

Paramus, NJ-Wills Eye Institute, Philadelphia, has chosen Topcon Medical Systems' new software (EyeRoute, Topcon) with the goal of improving workflow and ensuring seamless interconnectivity of its devices so that diagnostic information is made available virtually at any time from any location.

Ophthalmologist-in-chief at Wills Eye, Julia A. Haller, MD, said "Using [the software system], diagnostic data from various instruments can be channeled into a single imaging center that consolidates patients' and surgeons' needs with great ease. The system also improves patient information exchange with referring physicians in the institute's worldwide community."

Katrin Teigeler, vice-president of marketing at Topcon, said, "[The software system]-based, wholly centralized system greatly improves communication and information transfer not only within the hospital itself, but among the referring practices in the community as well, which saves time and money."

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.